India's first dengue vaccine expected in market by mid-2027

India's first dengue vaccine is expected to be available in the private market in the first half of 2027. Takeda Pharma and Dr Reddy's Laboratories have signed an agreement under which Dr Reddy's will promote and distribute the Japanese firm's vaccine QDENGA across India's private market for paediatric and adult vaccination. India's Central Drugs Standard Control Organisation granted QDENGA marketing authorisation in July for those aged 4 to 60. A statement said inclusion in the public immunisation programme remains a key ambition. Price details were not available.

Written by AI from Times of India — Top · not yet reviewed by an editor · Published 19 Sept 2026, 3:08 am IST

Source

Times of India — Top · read the original report ↗

#dengue#vaccine#qdenga#dr reddys#takeda#cdsco

Desk check · compared with the source

What the desk checked (5)

India's first dengue vaccine is expected in the private market in the first half of 2027. — Stated in source as an expectation; timeline appears in source without named official attribution.
Takeda Pharma and Dr Reddy's Laboratories have an agreement for Dr Reddy's to promote and distribute QDENGA in India's private market. — Presented as fact in source, based on a company statement.
CDSCO granted QDENGA marketing authorisation in July for those aged 4 to 60 years. — Figures and regulator name appear in source; attributed to India's Central Drugs Standard Control Organisation.
Inclusion in India's public immunisation programme remains a key ambition. — Direct quote attributed to an unnamed statement in the source.
Vaccine price details were not available. — Explicitly noted in source; no figure given.

Written by AI from Times of India — Top · not yet reviewed by an editor · How we use AI · Report an error

Analysts’ view opinion

AI Policy Analyst

The route this dengue vaccine is taking into India — private market first, public programme only as a stated ambition — mirrors how most new vaccines have entered the country in recent years. That means the earliest recipients will largely be urban households able to pay out of pocket, even though dengue's burden is not confined to that group. With no price disclosed, it is too early to judge how much this agreement shifts the public health picture.

CDSCO's marketing authorisation for ages 4–60 is a regulatory clearance, not a decision to include the vaccine in the public immunisation programme — that is a separate policy and budget call.
A private-market first launch builds real-world experience on supply, provider training and demand, but it also front-loads access to those who can afford it.
The statement frames public programme inclusion only as a "key ambition"; the story carries no timeline or commitment on when or how that might happen.
The absence of price detail is the single biggest gap here, since for multi-dose vaccines the household cost largely determines uptake.
A first-half-2027 timeline gives states room to strengthen vector control and surveillance — the vaccine supplements those measures rather than replacing them.

What to watch — Watch for the announced price and dosing schedule, and for any signal that national immunisation advisory processes have begun evaluating the vaccine for public programme inclusion.

The story establishes nothing about price, number of doses, any timeline for public programme inclusion, or the vaccine's efficacy and safety profile — and the 2027 date is itself an expectation, not a confirmed launch.

Deep dive

Research brief · 7 facts · 3 dates · exam-ready

The brief

Context

Dengue, a mosquito-borne viral disease, has had no licensed vaccine available in India so far. Japanese drugmaker Takeda Pharma's dengue vaccine QDENGA received marketing authorisation from India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), in July for people aged 4 to 60 years. Takeda has now tied up with Hyderabad-based Dr Reddy's Laboratories to promote and distribute the vaccine in India's private market for both paediatric and adult vaccination, with availability expected in the first half of 2027.

Key facts

India's first dengue vaccine is expected to be available in the private market in the first half of 2027.
Takeda Pharma and Dr Reddy's Laboratories have signed an agreement for promotion and distribution of QDENGA in India.
Under the deal, Dr Reddy's will promote and distribute QDENGA across India's private market for paediatric and adult vaccination.
The Central Drugs Standard Control Organisation (CDSCO) granted QDENGA marketing authorisation in July for individuals aged 4 to 60 years.
A statement said inclusion in India's public immunisation programme 'remains a key ambition'.
Private-market availability is described as a pathway for eligible individuals to access the vaccine.
Details of the vaccine's price were not available.

Timeline

JulyCDSCO grants marketing authorisation to QDENGA for individuals aged 4 to 60 years.
After the authorisation (date not stated in the source)Takeda Pharma and Dr Reddy's Laboratories enter into a promotion and distribution agreement for India's private market.
First half of 2027India's first dengue vaccine expected to be available in the private market.

Who has a stake

Takeda Pharma — Japanese manufacturer of QDENGA; seeks market entry and eventual public programme inclusion in India.
Dr Reddy's Laboratories — Will promote and distribute QDENGA across India's private market for paediatric and adult vaccination.
Central Drugs Standard Control Organisation (CDSCO) — India's drug regulator; granted the marketing authorisation in July for ages 4 to 60.
Eligible individuals aged 4 to 60 years — Potential beneficiaries who can access the vaccine through the private market.
Government public immunisation programme — Inclusion of the vaccine remains a stated key ambition, which would determine wider free access.

Why it matters

Dengue is a recurring public health burden in India, and until now no dengue vaccine has been available in the country. A private-market launch in 2027 would create the first access route for eligible people aged 4 to 60, but pricing is not yet known and inclusion in the public immunisation programme is only an ambition at this stage, which will shape how equitable access turns out to be.

UPSC angle

Prelims pointers

QDENGA is Takeda Pharma's dengue vaccine; Dr Reddy's Laboratories will promote and distribute it in India's private market.
CDSCO, India's drug regulator, granted QDENGA marketing authorisation in July for ages 4 to 60 years.
Expected private-market availability in India: first half of 2027.
The vaccine is authorised for both paediatric and adult vaccination in the approved age band.
Inclusion in India's public immunisation programme is stated as a key ambition, not yet decided.
Price details of the vaccine were not available as per the source.

Mains framing

India's first dengue vaccine reaching the market marks a shift in the country's approach to a mosquito-borne disease that has so far been tackled largely through vector control and case management. Regulatory clearance by CDSCO in July for ages 4 to 60, followed by a Takeda–Dr Reddy's distribution tie-up, signals that the first access route will be the private market in the first half of 2027 rather than the public system. This raises familiar questions of affordability and equity: with price details not disclosed, out-of-pocket purchase may limit uptake to better-off households, even as the statement calls inclusion in the public immunisation programme a 'key ambition'. The age restriction of 4 to 60 years also leaves younger children and the elderly outside the authorised group. The way forward lies in transparent pricing, evidence generation on effectiveness in Indian epidemiological conditions, and a clear government decision pathway on whether and when the vaccine enters the public immunisation programme, while sustaining vector control and surveillance rather than treating vaccination as a substitute.

Key terms

QDENGA: Takeda Pharma's dengue vaccine, authorised in India for individuals aged 4 to 60 years.
CDSCO: Central Drugs Standard Control Organisation, India's drug regulator, which granted QDENGA marketing authorisation in July.
Marketing authorisation: Regulatory approval allowing a medicine or vaccine to be sold in a country for specified uses and age groups.
Private market availability: Sale through private hospitals, clinics and chemists on payment, as distinct from free supply via government programmes.
Public immunisation programme: Government-run vaccination programme; QDENGA's inclusion in it is stated as a key ambition, not yet approved.

Practice questions

Discuss the implications of launching India's first dengue vaccine through the private market before any decision on its inclusion in the public immunisation programme.
What role does the Central Drugs Standard Control Organisation play in vaccine approval in India? Illustrate with the case of QDENGA.
Vaccination alone cannot address India's dengue burden. Examine the complementary roles of vector control, surveillance and immunisation.

Grounded only in the source report — figures and dates are the source's, not inferred.

Next storyIndia says committed to energy security after US sanctions bill →

← All stories